MDSC

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
  • Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
  • In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
  • JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Thrombosis, TLR9, MDSC, Immunotherapy, Drug, Progression-free survival, Patient, Cancer, Bleeding, Society, University, Neoplasm, MD Anderson Cancer Center, Pancreas, FACS, Liver

Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.

Key Points: 
  • Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.
  • In PERIO-03, nelitolimod is delivered via the PEDD method with the TriSalus Infusion System using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • There were no immediate complications from the procedure, and there was no evidence of hemorrhage or thrombosis.
  • Local tumor progression-free survival rates across organs at one month, six months, and one year were 94%, 80%, and 70%, respectively.

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Uveal melanoma, MDSC, Webcast, Sale, Interest, Liver disease, Pressure, Policy, ICI, Cancer, Commercial Operating System, Liver, Investment, Patient, PFS, Tumor microenvironment, Marketing, FACS, Neoplasm, TME, MD, SITC, Growth, Immunotherapy, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Today marks an important milestone for TriSalus as we host our first quarterly earnings call as a public company.
  • The seven percent improvement in the third quarter of 2023 is due to increased factory volumes and improved operations efficiency.
  • Operating losses are $18.5 million and $40.0 million, respectively, for the third quarter and nine months ended September 30, 2023.

DELAYS AND INEQUITIES ROCK CANADA'S PUBLIC DRUG COVERAGE SYSTEM

Retrieved on: 
Tuesday, November 14, 2023
CAMH, MDSC, University of Toronto, Health Canada, University, Community mental health service, Risk, Government, Mental health, DSM-IV codes, University of British Columbia, Intussusception (medical disorder), BBB National Programs, Addiction, Health insurance, Nursing

Mood Disorders Society of Canada (MDSC) examined Canada's public reimbursement review process for mental illness drugs approved by Health Canada between 2012 and 2022.

Key Points: 
  • Mood Disorders Society of Canada (MDSC) examined Canada's public reimbursement review process for mental illness drugs approved by Health Canada between 2012 and 2022.
  • Time delays: the average time from Health Canada approval to public reimbursement was 949 days or just over 2.5 years after the medication was approved for Canadians.
  • Provincial disparity: the vast majority of new medications assessed for this report are not equitably accessible through public drug plans across the country or are not accessible at all.
  • "Yet, there are significant barriers impeding access to new medications through public drug plans, leaving the lives of many Canadians with mental illness at risk."

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023
MDSC, Consultant, Associate, Cancer immunotherapy, CD16, Therapy, Society for Immunotherapy of Cancer, Prostate cancer, MD, University, Myeloid-derived suppressor cell, GT, Doctor of Philosophy, Cell, Prostate, SITC, Immunotherapy, NK, Annual general meeting, PCA, Tumor microenvironment, Society, TME, PSMA, Hypoxia, Trike, Vaccine, Medicine

Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.

Key Points: 
  • Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.
  • However, lack of antigen-specific targeting, decreased numbers, and suppressive signals from the tumor microenvironment (TME) of Prostate Cancer (PCa), can negatively impact NK cell efficacy.
  • The TriKE molecules displayed improved tumor control, compared to IL-15 control or no treatment, in xenogeneic models of prostate cancer.
  • Society For Immunotherapy of Cancer (SITC) 2023 Annual Meeting – November 1-5, 2023

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Retrieved on: 
Saturday, November 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Patient, MDSC, Uveal melanoma, Fatigue, Nivolumab, T helper cell, DCR, Pancreas, PFS, Liver, Skin, FACS, SITC, NanoString Technologies, NK, Liver disease, Annual general meeting, Blood, TLR, Tumor microenvironment, University, Society, Progression-free survival, MD Anderson Cancer Center, Neoplasm, Society for Immunotherapy of Cancer, Medical imaging, Pharmaceutical industry, Immunotherapy, Cancer

The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.

Key Points: 
  • The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.
  • At the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab (n=7), the median PFS was 11.7 months with an 81% DCR.
  • At the data cutoff as of September 29, 2023, 56 patients were enrolled, with each having received at least one dose of SD-101.
  • Dr. Katz added, “These data reflect additional validation of our innovative immunotherapy approach for liver and pancreas tumors.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, Neoplasm, Patient, FRCP, MDSC, PRS, NSCLC, Poster, PD, Aes, UC, Publication, Vomiting, DCR, Diarrhea, Pembrolizumab, Metastasis, Associate professor, Safety, Conference, Doctor of Philosophy, MBBS, Data, Nausea, CD8, Rash, Cancer immunotherapy, Immunotherapy, Rock, SD, DRAGON, SITC, San Diego Convention Center, Biopsy, Annual general meeting, ORR, University, RECIST, Biomarker, Melanoma, Lung cancer, Society, Therapy, AE, Carcinoma, Spectrochimica Acta Part B, Dermatitis, PR, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging, Nightclub, Part

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MDSC, Pancreatic tumor, Pressure, Pancreas, Liver, Perfusion, TLR9, Drug, FACS, SITC, Annual general meeting, Pancreatic cancer, Immunotherapy, TLR, Tumor microenvironment, University, Safety, Society, MD Anderson Cancer Center, Patient, Society for Immunotherapy of Cancer, Medical imaging, Medical device, Pharmaceutical industry, Cancer

In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.

Key Points: 
  • In PERIO-03, SD-101 is delivered via PEDD with the TriSalus Infusion System® using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • The TriSalus Infusion System has an expandable SmartValve® and can interface with standard invasive blood pressure transducers for continuous pressure monitoring during infusion of a therapeutic.
  • This is a first-in-human experience for use of PEDD and retrograde venous infusion for delivery of an immunologic agent into pancreatic tumors.
  • We are excited to continue enrolling patients in this study.”
    “These data offer additional validation of our innovative immunotherapy approach for pancreatic tumors.

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Retrieved on: 
Monday, November 6, 2023
Actinium, MDSC, Society for Immunotherapy of Cancer, NYSE, Annual Meetings of the International Monetary Fund and the World Bank Group, Myeloid-derived suppressor cell, Poster, SITC, Immunotherapy, Immunity, CD33, Society, Actinium-225, Escape Room, Vaccine

The poster highlighted Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs), which uniformly express CD33.

Key Points: 
  • The poster highlighted Actimab-A's ability to target and deplete myeloid-derived suppressor cells (MDSCs), which uniformly express CD33.
  • MDSCs are a cell population of interest as they remodel the tumor environment and promote immune evasion.
  • Actinium believes Actimab-A has the potential to be used in combination with immunotherapy, including immune checkpoint inhibitors, to enhance antitumor immunity via targeted MDSC depletion.
  • Supportive data from the SITC presentation includes:
    Sandesh Seth, Actinium's Chairman and CEO, commented, "These data further increase our enthusiasm for Actimab-A's potential in solid tumor indications.